059 Atopic-eczema-associated fracture risk and oral corticosteroids: a population-based cohort study

J Matthewman,K Mansfield,D Prieto-Alhambra,A Mulick,L Smeeth,K Lowe,R Silverwood,S Langan

doi:10.1016/j.jid.2021.08.061

Abstract

Evidence suggests adults with atopic eczema have increased fracture risk. However, it is unclear whether oral corticosteroids explain the association. The objective of this study was to assess to what extent oral corticosteroids mediate the relationship between eczema and fracture risk. We performed a cohort study using English primary care (Clinical Practice Research Datalink) and hospital admissions (Hospital Episode Statistics) records (1998-2016). Participants were adults (18+) with eczema matched (on age, sex, and general practice) with up to five adults without eczema.

Highlights

First clinical experience with IMU-935, an orally available small molecule inhibitor of IL-17 TM Polasek1, F Fliegert2, I Betscheider2, M Groeppel2, D Vitt2, H Kohlhof2 and A Muehler2 1 Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, SA, Australia and 2 Immunic AG, Graefelfing, Germany The objectives of this clinical trial are to assess safety, tolerability, and pharmacokinetics of IMU-935
Pharmacokinetic evaluation showed the half-life of IMU-935 ranging from 16.5 to 31.0 hours and strict dose proportional increases of Cmax and area under the plasma concentration-time curve (AUC)
To gain further insights into paradoxical psoriasis (PXP) pathogenesis, we investigated molecular and cellular players putatively involved in PXP in the blood of patients with PXP (n1⁄415, of which 5 with resolved PXP) and age, sex and ethnicity-matched controls groups of healthy donors (HD, n1⁄415) and psoriasis patients before (Ps) and after 12 weeks of receiving TNFi without developing PXP (Ps TNFi)

Summary

Introduction

First clinical experience with IMU-935, an orally available small molecule inhibitor of IL-17 TM Polasek1, F Fliegert2, I Betscheider2, M Groeppel2, D Vitt2, H Kohlhof2 and A Muehler2 1 Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, SA, Australia and 2 Immunic AG, Graefelfing, Germany The objectives of this clinical trial are to assess safety, tolerability, and pharmacokinetics of IMU-935. In part A, healthy volunteers in cohorts of 8 subjects each were enrolled and received single ascending doses of IMU-935 (25 to 400 mg) or placebo (ratio 3:1). In part B, healthy volunteers will receive multiple ascending doses of IMU-935 or placebo for 14 days, and in part C, patients with moderate to severe plaque-type psoriasis will take either two different dose levels of IMU-935 or placebo.

Objectives

Results

Conclusion